5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?
Open Access
- 1 June 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (11) , 4644-4646
- https://doi.org/10.1182/blood-2002-11-3458
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatmentBlood, 2002
- CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter futureOncogene, 2002
- Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?JNCI Journal of the National Cancer Institute, 2002
- Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implicationsBritish Journal of Cancer, 2002
- Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous MelanomaJournal of Immunotherapy, 2002
- Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)Journal of Immunotherapy, 1999
- DNA methylation levels in acute human leukemiaCancer Letters, 1988